Hereditary Transthyretin Amyloidosis (HATTR)  Market Report

Global Hereditary Transthyretin Amyloidosis (HATTR) Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Mar 02, 2022
  • PAGES：188
  • REPORT CODE：GMM792208
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Hereditary Transthyretin Amyloidosis (HATTR) market report explains the definition, types, applications, major countries, and major players of the Hereditary Transthyretin Amyloidosis (HATTR) market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Alnylam Pharmaceuticals

    • Prothena

    • Akcea Therapeutics

    • Eidos Therapeutics

    • Corino Therapeutics Inc

    • Lonis Pharmaceuticals

    • Pfizer

    By Type:

    • Oral

    • Subcutaneous Injection

    • Others

    By End-User:

    • Hospital

    • Clinic

    • Others

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Hereditary Transthyretin Amyloidosis (HATTR) Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Hereditary Transthyretin Amyloidosis (HATTR) Outlook to 2028- Original Forecasts

    • 2.2 Hereditary Transthyretin Amyloidosis (HATTR) Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Hereditary Transthyretin Amyloidosis (HATTR) Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Hereditary Transthyretin Amyloidosis (HATTR) Market- Recent Developments

    • 6.1 Hereditary Transthyretin Amyloidosis (HATTR) Market News and Developments

    • 6.2 Hereditary Transthyretin Amyloidosis (HATTR) Market Deals Landscape

    7 Hereditary Transthyretin Amyloidosis (HATTR) Raw Materials and Cost Structure Analysis

    • 7.1 Hereditary Transthyretin Amyloidosis (HATTR) Key Raw Materials

    • 7.2 Hereditary Transthyretin Amyloidosis (HATTR) Price Trend of Key Raw Materials

    • 7.3 Hereditary Transthyretin Amyloidosis (HATTR) Key Suppliers of Raw Materials

    • 7.4 Hereditary Transthyretin Amyloidosis (HATTR) Market Concentration Rate of Raw Materials

    • 7.5 Hereditary Transthyretin Amyloidosis (HATTR) Cost Structure Analysis

      • 7.5.1 Hereditary Transthyretin Amyloidosis (HATTR) Raw Materials Analysis

      • 7.5.2 Hereditary Transthyretin Amyloidosis (HATTR) Labor Cost Analysis

      • 7.5.3 Hereditary Transthyretin Amyloidosis (HATTR) Manufacturing Expenses Analysis

    8 Global Hereditary Transthyretin Amyloidosis (HATTR) Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Hereditary Transthyretin Amyloidosis (HATTR) Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Hereditary Transthyretin Amyloidosis (HATTR) Export by Region (Top 10 Countries) (2017-2028)

    9 Global Hereditary Transthyretin Amyloidosis (HATTR) Market Outlook by Types and Applications to 2022

    • 9.1 Global Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Oral Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Subcutaneous Injection Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Others Consumption and Growth Rate (2017-2022)

    • 9.2 Global Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Clinic Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Others Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Hereditary Transthyretin Amyloidosis (HATTR) Market Analysis and Outlook till 2022

    • 10.1 Global Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

      • 10.2.2 Canada Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

      • 10.2.3 Mexico Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

      • 10.3.2 UK Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

      • 10.3.3 Spain Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

      • 10.3.4 Belgium Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

      • 10.3.5 France Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

      • 10.3.6 Italy Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

      • 10.3.7 Denmark Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

      • 10.3.8 Finland Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

      • 10.3.9 Norway Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

      • 10.3.10 Sweden Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

      • 10.3.11 Poland Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

      • 10.3.12 Russia Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

      • 10.3.13 Turkey Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

      • 10.4.2 Japan Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

      • 10.4.3 India Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

      • 10.4.4 South Korea Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

      • 10.4.5 Pakistan Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

      • 10.4.6 Bangladesh Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

      • 10.4.7 Indonesia Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

      • 10.4.8 Thailand Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

      • 10.4.9 Singapore Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

      • 10.4.10 Malaysia Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

      • 10.4.11 Philippines Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

      • 10.4.12 Vietnam Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

      • 10.5.2 Colombia Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

      • 10.5.3 Chile Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

      • 10.5.4 Argentina Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

      • 10.5.5 Venezuela Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

      • 10.5.6 Peru Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

      • 10.5.7 Puerto Rico Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

      • 10.5.8 Ecuador Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

      • 10.6.2 Kuwait Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

      • 10.6.3 Oman Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

      • 10.6.4 Qatar Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

      • 10.7.2 South Africa Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

      • 10.7.3 Egypt Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

      • 10.7.4 Algeria Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

      • 10.8.2 New Zealand Hereditary Transthyretin Amyloidosis (HATTR) Consumption (2017-2022)

    11 Global Hereditary Transthyretin Amyloidosis (HATTR) Competitive Analysis

    • 11.1 Alnylam Pharmaceuticals

      • 11.1.1 Alnylam Pharmaceuticals Company Details

      • 11.1.2 Alnylam Pharmaceuticals Hereditary Transthyretin Amyloidosis (HATTR) Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Alnylam Pharmaceuticals Hereditary Transthyretin Amyloidosis (HATTR) Main Business and Markets Served

      • 11.1.4 Alnylam Pharmaceuticals Hereditary Transthyretin Amyloidosis (HATTR) Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 Prothena

      • 11.2.1 Prothena Company Details

      • 11.2.2 Prothena Hereditary Transthyretin Amyloidosis (HATTR) Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 Prothena Hereditary Transthyretin Amyloidosis (HATTR) Main Business and Markets Served

      • 11.2.4 Prothena Hereditary Transthyretin Amyloidosis (HATTR) Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 Akcea Therapeutics

      • 11.3.1 Akcea Therapeutics Company Details

      • 11.3.2 Akcea Therapeutics Hereditary Transthyretin Amyloidosis (HATTR) Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 Akcea Therapeutics Hereditary Transthyretin Amyloidosis (HATTR) Main Business and Markets Served

      • 11.3.4 Akcea Therapeutics Hereditary Transthyretin Amyloidosis (HATTR) Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 Eidos Therapeutics

      • 11.4.1 Eidos Therapeutics Company Details

      • 11.4.2 Eidos Therapeutics Hereditary Transthyretin Amyloidosis (HATTR) Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 Eidos Therapeutics Hereditary Transthyretin Amyloidosis (HATTR) Main Business and Markets Served

      • 11.4.4 Eidos Therapeutics Hereditary Transthyretin Amyloidosis (HATTR) Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Corino Therapeutics Inc

      • 11.5.1 Corino Therapeutics Inc Company Details

      • 11.5.2 Corino Therapeutics Inc Hereditary Transthyretin Amyloidosis (HATTR) Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Corino Therapeutics Inc Hereditary Transthyretin Amyloidosis (HATTR) Main Business and Markets Served

      • 11.5.4 Corino Therapeutics Inc Hereditary Transthyretin Amyloidosis (HATTR) Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    • 11.6 Lonis Pharmaceuticals

      • 11.6.1 Lonis Pharmaceuticals Company Details

      • 11.6.2 Lonis Pharmaceuticals Hereditary Transthyretin Amyloidosis (HATTR) Sales, Price, Value and Gross Profit (2017-2022)

      • 11.6.3 Lonis Pharmaceuticals Hereditary Transthyretin Amyloidosis (HATTR) Main Business and Markets Served

      • 11.6.4 Lonis Pharmaceuticals Hereditary Transthyretin Amyloidosis (HATTR) Product Portfolio

      • 11.6.5 Recent Research and Development Strategies

    • 11.7 Pfizer

      • 11.7.1 Pfizer Company Details

      • 11.7.2 Pfizer Hereditary Transthyretin Amyloidosis (HATTR) Sales, Price, Value and Gross Profit (2017-2022)

      • 11.7.3 Pfizer Hereditary Transthyretin Amyloidosis (HATTR) Main Business and Markets Served

      • 11.7.4 Pfizer Hereditary Transthyretin Amyloidosis (HATTR) Product Portfolio

      • 11.7.5 Recent Research and Development Strategies

    12 Global Hereditary Transthyretin Amyloidosis (HATTR) Market Outlook by Types and Applications to 2028

    • 12.1 Global Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Oral Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Subcutaneous Injection Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.3 Global Others Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Clinic Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Hereditary Transthyretin Amyloidosis (HATTR) Market Analysis and Outlook to 2028

    • 13.1 Global Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

      • 13.2.2 Canada Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

      • 13.3.2 UK Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

      • 13.3.3 Spain Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

      • 13.3.5 France Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

      • 13.3.6 Italy Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

      • 13.3.8 Finland Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

      • 13.3.9 Norway Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

      • 13.3.11 Poland Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

      • 13.3.12 Russia Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

      • 13.4.2 Japan Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

      • 13.4.3 India Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

      • 13.5.3 Chile Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

      • 13.5.6 Peru Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

      • 13.6.3 Oman Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Hereditary Transthyretin Amyloidosis (HATTR)

    • Figure of Hereditary Transthyretin Amyloidosis (HATTR) Picture

    • Table Global Hereditary Transthyretin Amyloidosis (HATTR) Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Hereditary Transthyretin Amyloidosis (HATTR) Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Oral Consumption and Growth Rate (2017-2022)

    • Figure Global Subcutaneous Injection Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Hospital Consumption and Growth Rate (2017-2022)

    • Figure Global Clinic Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Hereditary Transthyretin Amyloidosis (HATTR) Consumption by Country (2017-2022)

    • Table North America Hereditary Transthyretin Amyloidosis (HATTR) Consumption by Country (2017-2022)

    • Figure United States Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Figure Canada Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Figure Mexico Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Table Europe Hereditary Transthyretin Amyloidosis (HATTR) Consumption by Country (2017-2022)

    • Figure Germany Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Figure UK Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Figure Spain Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Figure Belgium Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Figure France Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Figure Italy Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Figure Denmark Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Figure Finland Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Figure Norway Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Figure Sweden Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Figure Poland Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Figure Russia Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Figure Turkey Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Table APAC Hereditary Transthyretin Amyloidosis (HATTR) Consumption by Country (2017-2022)

    • Figure China Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Figure Japan Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Figure India Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Figure South Korea Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Figure Thailand Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Figure Singapore Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Figure Philippines Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Table South America Hereditary Transthyretin Amyloidosis (HATTR) Consumption by Country (2017-2022)

    • Figure Brazil Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Figure Colombia Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Figure Chile Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Figure Argentina Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Figure Peru Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Table GCC Hereditary Transthyretin Amyloidosis (HATTR) Consumption by Country (2017-2022)

    • Figure Bahrain Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Figure Oman Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Figure Qatar Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Table Africa Hereditary Transthyretin Amyloidosis (HATTR) Consumption by Country (2017-2022)

    • Figure Nigeria Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Figure South Africa Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Figure Egypt Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Figure Algeria Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Table Oceania Hereditary Transthyretin Amyloidosis (HATTR) Consumption by Country (2017-2022)

    • Figure Australia Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Hereditary Transthyretin Amyloidosis (HATTR) Consumption and Growth Rate (2017-2022)

    • Table Alnylam Pharmaceuticals Company Details

    • Table Alnylam Pharmaceuticals Hereditary Transthyretin Amyloidosis (HATTR) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Alnylam Pharmaceuticals Hereditary Transthyretin Amyloidosis (HATTR) Main Business and Markets Served

    • Table Alnylam Pharmaceuticals Hereditary Transthyretin Amyloidosis (HATTR) Product Portfolio

    • Table Prothena Company Details

    • Table Prothena Hereditary Transthyretin Amyloidosis (HATTR) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Prothena Hereditary Transthyretin Amyloidosis (HATTR) Main Business and Markets Served

    • Table Prothena Hereditary Transthyretin Amyloidosis (HATTR) Product Portfolio

    • Table Akcea Therapeutics Company Details

    • Table Akcea Therapeutics Hereditary Transthyretin Amyloidosis (HATTR) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Akcea Therapeutics Hereditary Transthyretin Amyloidosis (HATTR) Main Business and Markets Served

    • Table Akcea Therapeutics Hereditary Transthyretin Amyloidosis (HATTR) Product Portfolio

    • Table Eidos Therapeutics Company Details

    • Table Eidos Therapeutics Hereditary Transthyretin Amyloidosis (HATTR) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Eidos Therapeutics Hereditary Transthyretin Amyloidosis (HATTR) Main Business and Markets Served

    • Table Eidos Therapeutics Hereditary Transthyretin Amyloidosis (HATTR) Product Portfolio

    • Table Corino Therapeutics Inc Company Details

    • Table Corino Therapeutics Inc Hereditary Transthyretin Amyloidosis (HATTR) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Corino Therapeutics Inc Hereditary Transthyretin Amyloidosis (HATTR) Main Business and Markets Served

    • Table Corino Therapeutics Inc Hereditary Transthyretin Amyloidosis (HATTR) Product Portfolio

    • Table Lonis Pharmaceuticals Company Details

    • Table Lonis Pharmaceuticals Hereditary Transthyretin Amyloidosis (HATTR) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Lonis Pharmaceuticals Hereditary Transthyretin Amyloidosis (HATTR) Main Business and Markets Served

    • Table Lonis Pharmaceuticals Hereditary Transthyretin Amyloidosis (HATTR) Product Portfolio

    • Table Pfizer Company Details

    • Table Pfizer Hereditary Transthyretin Amyloidosis (HATTR) Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Hereditary Transthyretin Amyloidosis (HATTR) Main Business and Markets Served

    • Table Pfizer Hereditary Transthyretin Amyloidosis (HATTR) Product Portfolio

    • Figure Global Oral Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Subcutaneous Injection Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinic Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast by Country (2022-2028)

    • Table North America Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast by Country (2022-2028)

    • Figure United States Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast by Country (2022-2028)

    • Figure Germany Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast by Country (2022-2028)

    • Figure China Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast by Country (2022-2028)

    • Figure Brazil Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast by Country (2022-2028)

    • Figure Australia Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Hereditary Transthyretin Amyloidosis (HATTR) Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US